Eucardia successfully closed a new capital increase
July, 24th 2017
Eucardia has successfully closed a new capital increase, subscribed by private investors.
Marco Bottaro, CEO of Eucardia, declares: «The transaction completed today is the result of a wonderful teamwork and of the enthusiasm of the new members. It marks a turning point in Eucardia's growth path. Thanks to this capital increase, and to the recent victory of the Marzotto Award, we can rapidly proceed to the pre-clinical validation of our device».
The operation was conducted by the Eucardia team with the precious support of Be-come srl, an innovative firm that designs high-profile solutions for innovators and changemakers. Be-come, in particular Massimiliano D'Amico and Michela Borin, coordinated the transaction from the legal and arrangement point of view.
The new funding will be used to consolidate the team and to target important goals: thanks to a protocol on animal testing and other ongoing experiments, the company expects to complete the proof-of-evidence phase and to approach the pre-clinical phase in 2018.
«The interest shown on Eucardia confirms that the life-science market can attract large private investments in Italy» added Emanuele Ottina, Head of Finance and Fund Raising of Eucardia, «a great news for innovators made in Italy and a good starting point for the next funding round».
Marco Bottaro, CEO of Eucardia, declares: «The transaction completed today is the result of a wonderful teamwork and of the enthusiasm of the new members. It marks a turning point in Eucardia's growth path. Thanks to this capital increase, and to the recent victory of the Marzotto Award, we can rapidly proceed to the pre-clinical validation of our device».
The operation was conducted by the Eucardia team with the precious support of Be-come srl, an innovative firm that designs high-profile solutions for innovators and changemakers. Be-come, in particular Massimiliano D'Amico and Michela Borin, coordinated the transaction from the legal and arrangement point of view.
The new funding will be used to consolidate the team and to target important goals: thanks to a protocol on animal testing and other ongoing experiments, the company expects to complete the proof-of-evidence phase and to approach the pre-clinical phase in 2018.
«The interest shown on Eucardia confirms that the life-science market can attract large private investments in Italy» added Emanuele Ottina, Head of Finance and Fund Raising of Eucardia, «a great news for innovators made in Italy and a good starting point for the next funding round».
Eucardia at the Lombardy Open Innovation Day Life Science
July, 6th 2017
|
Unicredit StartLab, Assolombarda and the Lombardy Life Sciences Cluster organized a meeting of 8 startups, investors and pharmaceutical and biomedical industries in early July. The aim of the convention was to deepen the main trends in life sciences innovation and to promote open innovation processes and collaboration between startups and participating companies.
Francesca Parravicini, founder of Eucardia, presented the company and the progress of the device, stirring up the interest of the audience. |
Made in Italy 2020: Eucardia with iStarter at the House of Parliament
April, 10th 2017
|
The Made in Italy 2020 is an event organized by iStarter, the Italian accelerator that helps new companies in our country to grow overseas.
It consists of an international tour that includes three stages: the first one has been in London in April, then the Made In Italy 2020 will move to Beijing in October, where over 100 international investors are expected, then in New York in January 2018. IStarter brought to London 10 Italian startups: apart from Eucardia, the other companies were all digital startups (Primo, ChatSim, Debut, Velasca, Viniexport, Worldz and BeMyEye). The event closed with a gala at the English Parliament: a further opportunity of networking for startups and Italian and foreign investors. |
|
Eucardia celebrates with friends the Marzotto Award
February, 9th 2017
|
|
In December 2016 the innovativeness and competitiveness of the Heart Damper allowed Eucardia to stand out among over 700 candidates and win the Gaetano Marzotto Award, the most coveted in Italy in the world of start-ups. Eucardia wanted to share the gratitude and satisfaction for this prime step in its path with members and friends and celebrated with them on the evening of 9th, February at Clubhouse Brera, in the heart of Milan. |
Eucardia in the top 25 emerging companies at the European Venture Summit
December, 7th 2016
|
Filtered from over 1.000 emerging european companies and 500 pitches held throughout Europe Unlimited and TechTour’s 2016 calendar, Eucardia presented during the 10th edition of the European Venture Summit (EVS), which took place in Düsseldorf, on 5 & 6 December.
The EVS finds and evaluates and awards the most promising entrepreneurs in the high technology sector by providing access to top-level international partners, advisors and financiers. Eucardia, presented by the CEO, Marco Bottaro, was awarded as part of the Top 25 companies, identified by a jury of investors and industry representatives. |
Eucardia won the Marzotto Award!
December, 1st 2016
Emerging among 700 startups, Eucardia won the Award for Enterprise, the most coveted prize of the Gaetano Marzotto Award: in Italy, the most important competition dedicated to startups. The Award for Enterprise consists of a grant of 300,000 Euros and a coaching course with CUOA.
|
|
Above and on the right, Roberto Parravicini and Francesca Parravicini withdraw the award on behalf of the Eucardia team.
With them, Matteo Marzotto, president of Progetto Marzotto; Riccardo Illy, president of the jury;
Emil Abirascid, chairman of the Selection Committee, and Cristiano Seganfreddo, general manager of Progetto Marzotto.
With them, Matteo Marzotto, president of Progetto Marzotto; Riccardo Illy, president of the jury;
Emil Abirascid, chairman of the Selection Committee, and Cristiano Seganfreddo, general manager of Progetto Marzotto.
Riccardo Illy, president of the jury, emphasized the revolutionary impact of the Heart Damper.
During the final, held in Rome at La Lanterna by Massimiliano Fuksas, he read the motivation that prompted the jury to reward Eucardia: «Despite being in the early stages of development, Eucardia presents a high level of ambition. Eucardia addresses the patients with heart failure, a pathological condition unfortunately already widespread and growing, enabling them to extend and improve the quality of life. The jury appreciated the innovativeness and competitiveness of the product, in a sector where alternative therapeutic options are still limited and inconclusive for most patients. They were also detected the team's committment of quality and the appropriate level of patent protection at international level».
During the final, held in Rome at La Lanterna by Massimiliano Fuksas, he read the motivation that prompted the jury to reward Eucardia: «Despite being in the early stages of development, Eucardia presents a high level of ambition. Eucardia addresses the patients with heart failure, a pathological condition unfortunately already widespread and growing, enabling them to extend and improve the quality of life. The jury appreciated the innovativeness and competitiveness of the product, in a sector where alternative therapeutic options are still limited and inconclusive for most patients. They were also detected the team's committment of quality and the appropriate level of patent protection at international level».
Eucardia in the final of the Marzotto Award
November, 8th 2016
We are glad to announce that Eucardia is part of the group of five finalist companies of the sixth edition of Gaetano Marzotto Award, the most important competition dedicated to italian innovators.
|
Conceived in 2010 by Giannino Marzotto to help create an italian innovation platform, the Marzotto Award gives away a prize pool of over € 2 million, including cash prizes and flanking paths. Inspired by the figure of Gaetano Marzotto, the Award aims to offer a chance to new entrepreneurs and future builders who are able to bring together innovation, business and society, in a framework of open innovation and an increasing internationalization.
Eucardia enrolled at the Marzotto Award with the hope of winning the Award for Enterprise, “for the best innovative company with capacity to generate significant positive impact in the local social, cultural or environmental”. |
The winners of the various categories will be revealed on December, the 1st in Rome, during the award ceremony.
Eucardia won the Best Presentation Award at the AHVF
October 18th, 2016
Eucardia won the Best Presentation Award at the Alpine High-tech Venture Forum (AHVF), which took place in Lausanne, on October 18th.
|
The AHVF is a unique event for the most innovative entrepreneurs operating in Switzerland and its surrounding regions focused on Life Sciences, Clean Technology and Information Technology to meet and present themselves to active international investors and corporations seeking for investment and partnerships.
The Best Presentation Awards grants Eucardia access to the 10th edition of the European Venture Summit (EVS) on 5 & 6 December, in Düsseldorf. Europe Unlimited’s series of 2016 regional and sector focused contests and forums culminate to the continent’s biggest venture marketplace uniting 100+ award winning entrepreneurs and 100+ investors. |
Eucardia at the Life Science Innovation Day
September 26th, 2016
|
Eucardia has been selected by UniCredit Start Lab team to present during the Life Science Innovation Day, open innovation initiative dedicated to the world of biotechnology, medical devices, and health care services. On September, 26 Marco Bottaro, CEO of Eucardia, presented Eucardia and the developments of the Heart Damper project, winning the interest of the audience. |
